Prevalence of mutations associated with antimalarial drugs in Plasmodium falciparum isolates prior to the introduction of sulphadoxine-pyrimethamine as first-line treatment in Iran
2007

Mutations in Malaria Parasites in Iran

Sample size: 206 publication Evidence: high

Author Information

Author(s): Zakeri Sedigheh, Afsharpad Mandana, Raeisi Ahmad, Djadid Navid Dinparast

Primary Institution: Malaria and Vector Research Group, Biotechnology Research Center, Institut Pasteur of Iran

Hypothesis

The study aims to assess the patterns and prevalence of resistance to chloroquine and sulphadoxine-pyrimethamine in Plasmodium falciparum in Iran.

Conclusion

Chloroquine should be withdrawn from the treatment strategy in Iran, while sulphadoxine-pyrimethamine may remain the treatment of choice for uncomplicated malaria.

Supporting Evidence

  • All P. falciparum isolates carried the 108N mutation.
  • 98.5% of patients carried both 108N and 59R mutations.
  • The prevalence of pfdhps 437G mutation was 17% in Chabahar and 33% in Sarbaz.
  • 98% of isolates carried the pfcrt 76T mutation.
  • Eight distinct haplotypes were identified among the samples.

Takeaway

The study found that many malaria parasites in Iran are resistant to chloroquine, so doctors should stop using it, but they can still use another drug called sulphadoxine-pyrimethamine for treatment.

Methodology

The study used PCR/RFLP methods to genotype mutations in 206 Plasmodium falciparum isolates collected from patients in Iran.

Limitations

The study may not represent all regions of Iran as it focused on specific districts.

Participant Demographics

Participants included Iranian, Afghani, and Pakistani nationals aged from 1 to over 60 years.

Digital Object Identifier (DOI)

10.1186/1475-2875-6-148

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication